Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabela Bobillo

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Leukemia|May 13, 2020
Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapyJuan C Nieto, Elisa Roldán, Isabel Jiménez, et al.
Ejhaem|November 29, 2023
PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphomaMarta Ligero, Marc Simó, Cecilia Carpio, et al.
Expert Review of Anticancer Therapy|February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphomaM Lia Palomba, Paola Ghione, Anik R Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2024
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular LymphomaPaola Ghione, M Lia Palomba, Markqayne D Ray, et al.
Haematologica|October 20, 2022
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 studyPaola Ghione, M Lia Palomba, Hervé Ghesquieres, et al.
Journal of Neuro-Oncology|July 22, 2020
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibitionIsabel Jiménez, Júlia Carabia, Sabela Bobillo, et al.
Blood|June 9, 2022
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphomaPaola Ghione, M Lia Palomba, Anik R Patel, et al.
Biomarker Research|May 21, 2021
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemiaIsabel Jiménez, Bárbara Tazón-Vega, Pau Abrisqueta, et al.
Haematologica|February 22, 2020
Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomasSabela Bobillo, Marta Crespo, Laura Escudero, et al.
Blood|October 15, 2013
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemiaPau Abrisqueta, Neus Villamor, María José Terol, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Leukemia|May 13, 2020
Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapyJuan C Nieto, Elisa Roldán, Isabel Jiménez, et al.
Ejhaem|November 29, 2023
PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphomaMarta Ligero, Marc Simó, Cecilia Carpio, et al.
Expert Review of Anticancer Therapy|February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphomaM Lia Palomba, Paola Ghione, Anik R Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2024
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular LymphomaPaola Ghione, M Lia Palomba, Markqayne D Ray, et al.
Haematologica|October 20, 2022
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 studyPaola Ghione, M Lia Palomba, Hervé Ghesquieres, et al.
Journal of Neuro-Oncology|July 22, 2020
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibitionIsabel Jiménez, Júlia Carabia, Sabela Bobillo, et al.
Blood|June 9, 2022
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphomaPaola Ghione, M Lia Palomba, Anik R Patel, et al.
Biomarker Research|May 21, 2021
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemiaIsabel Jiménez, Bárbara Tazón-Vega, Pau Abrisqueta, et al.
Haematologica|February 22, 2020
Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomasSabela Bobillo, Marta Crespo, Laura Escudero, et al.
Blood|October 15, 2013
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemiaPau Abrisqueta, Neus Villamor, María José Terol, et al.
Pageof 4